Related references
Note: Only part of the references are listed.Newborn Screening for Spinal Muscular Atrophy: Ontario Testing and Follow-up Recommendations
Hugh J. McMillan et al.
CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES (2021)
Systematic literature review of the economic burden of spinal muscular atrophy and economic evaluations of treatments
Tamara Dangouloff et al.
ORPHANET JOURNAL OF RARE DISEASES (2021)
Risdiplam in Type 1 Spinal Muscular Atrophy
Giovanni Baranello et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Therapeutic interventions for spinal muscular atrophy: preclinical and early clinical development opportunities
Laurent Servais et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2021)
Beyond copy number: A new, rapid, and versatile method for sequencing the entire SMN2 gene in SMA patients
Laura Blasco-Perez et al.
HUMAN MUTATION (2021)
Newborn screening programs for spinal muscular atrophy worldwide: Where we stand and where to go
Tamara Dangouloff et al.
NEUROMUSCULAR DISORDERS (2021)
High-throughput genetic newborn screening for spinal muscular atrophy by rapid nucleic acid extraction from dried blood spots and 384-well qPCR
Ludwig Czibere et al.
EUROPEAN JOURNAL OF HUMAN GENETICS (2020)
The implementation of newborn screening for spinal muscular atrophy: the Australian experience
Didu S. T. Kariyawasam et al.
GENETICS IN MEDICINE (2020)
244th ENMC international workshop: Newborn screening in spinal muscular atrophy May 10-12, 2019, Hoofdorp, The Netherlands
Tamara Dangouloff et al.
NEUROMUSCULAR DISORDERS (2020)
New treatments in spinal muscular atrophy: an overview of currently available data
Sithara Ramdas et al.
EXPERT OPINION ON PHARMACOTHERAPY (2020)
Implementation of population-based newborn screening reveals low incidence of spinal muscular atrophy
Denise M. Kay et al.
GENETICS IN MEDICINE (2020)
Correspondence on: Discrepancy in Spinal Muscular Atrophy Incidence findings in newborn screening programs: the influence of carrier screening? by Kay et al
Tamara Dangouloff et al.
GENETICS IN MEDICINE (2020)
Newborn screening for SMA in Southern Belgium
Francois Boemer et al.
NEUROMUSCULAR DISORDERS (2019)
Neurofilament as a potential biomarker for spinal muscular atrophy
Basil T. Darras et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2019)
Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study
Darryl C. De Vivo et al.
NEUROMUSCULAR DISORDERS (2019)
Clinical Evidence Supporting Early Treatment Of Patients With Spinal Muscular Atrophy: Current Perspectives
Tamara Dangouloff et al.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2019)
A Novel System for Spinal Muscular Atrophy Screening in Newborns: Japanese Pilot Study
Masakazu Shinohara et al.
INTERNATIONAL JOURNAL OF NEONATAL SCREENING (2019)
One Year of Newborn Screening for SMA - Results of a German Pilot Project
Katharina Vill et al.
JOURNAL OF NEUROMUSCULAR DISEASES (2019)
Pilot study of population-based newborn screening for spinal muscular atrophy in New York state
Jennifer N. Kraszewski et al.
GENETICS IN MEDICINE (2018)
Time Is Motor Neuron: Therapeutic Window and Its Correlation with Pathogenetic Mechanisms in Spinal Muscular Atrophy
Alessandra Govoni et al.
MOLECULAR NEUROBIOLOGY (2018)
Presymptomatic Diagnosis of Spinal Muscular Atrophy Through Newborn Screening
Yin-Hsiu Chien et al.
JOURNAL OF PEDIATRICS (2017)
Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy
J. R. Mendell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy
R. S. Finkel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Natural history of infantile-onset spinal muscular atrophy
Stephen J. Kolb et al.
ANNALS OF NEUROLOGY (2017)
Newborn and Carrier Screening for Spinal Muscular Atrophy
Thomas W. Prior et al.
AMERICAN JOURNAL OF MEDICAL GENETICS PART A (2010)
A feasibility study for the newborn screening of spinal muscular atrophy
Robert E. Pyatt et al.
GENETICS IN MEDICINE (2006)